Bedrijfsoverzicht
Klotho Neurosciences Inc. is a biotechnology entity dedicated to the development of therapeutic medicines aimed at treating complex conditions including cancer, cardiovascular disorders, and neurodegenerative diseases. The company operates within the broader healthcare sector, specifically focusing on the biotechnology industry where innovation in gene therapy represents a significant segment of medical advancement. According to the latest available data, the company possesses a market capitalization of $56.66M, while its annual revenue and employee count are not disclosed in the current financial reporting, with the employee figure listed as 3. The valuation metric of $56.66M market cap indicates that the market values the company's pipeline assets and intellectual property as its primary drivers of value, rather than current earnings or sales volume. This capitalization suggests the company is in an early-stage development phase typical for biotechnology firms that prioritize research and development expenditures over immediate profitability. The limited employee count combined with a modest market cap reflects the high-risk, high-reward nature of the industry, where value is often concentrated in the potential success of lead product candidates such as KLTO-101 and KLTO-202.
Financiële gezondheid
Klotho Neurosciences reports a net income of $-11,290,061 for the trailing twelve months, while revenue, EBITDA, and price-to-sales metrics are not currently reported. The substantial gap between reported revenue (which is N/A) and the significant negative net income reveals a cost structure dominated by high operational expenses, likely driven by research, development, and regulatory compliance costs inherent in biotechnology. The company's free cash flow stands at $-5,885,180, indicating a continuous cash burn that limits immediate financial flexibility and necessitates reliance on external funding sources or existing cash reserves. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which indicates that the company has not yet achieved profitability or scaled operations to generate positive margins from its revenue streams. On the balance sheet, the company holds $7.35M in cash and maintains $0 in debt, creating a situation where total liabilities are minimal relative to liquid assets. This balance sheet structure is inherently conservative regarding leverage, as the absence of debt eliminates interest obligations, though the lack of a debt-to-equity ratio due to zero debt prevents a traditional leverage assessment. The current ratio is listed at 83.69, a figure that suggests an extremely high level of short-term liquidity relative to current liabilities, although the specific liability figures are not provided to fully contextualize this metric. Furthermore, the return on equity is -198.3% and the return on assets is -71.6%, metrics that reveal the company is currently diluting shareholder value and utilizing assets inefficiently in terms of generating positive returns, which is typical for pre-revenue biotech firms but highlights the financial pressure on management effectiveness.
Waarderingsbeoordeling
The trailing P/E ratio and forward P/E ratio are both listed as N/A, implying that without positive earnings, traditional earnings-based valuation metrics cannot be applied to assess the company's value trajectory. In the absence of a P/E ratio, the price-to-book ratio serves as a primary valuation anchor, standing at 3.72, which indicates that the market is currently pricing the company at a significant premium of 3.72 times its net asset value. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are also unavailable, suggesting that investors must rely heavily on the price-to-book metric and the company's asset base to gauge valuation rather than revenue multiples or enterprise value multiples. The stock's price action shows a 52-week high of $3.91 and a 52-week low of $0.11, defining a volatility range where the current trading price sits significantly closer to the high end of the historical range relative to the low. The beta value is recorded at 2.23, which indicates that the stock price is expected to be 2.23 times more volatile than the broader market, reflecting the heightened sensitivity of biotechnology stocks to market sentiment and sector-specific developments. This high beta confirms that the equity carries substantial systematic risk, making the share price susceptible to sharp fluctuations driven by clinical trial results or regulatory approvals rather than traditional earnings growth.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, meaning that historical growth rates cannot be calculated due to the lack of comparable prior period financial data in the current reporting window. Since the company does not currently generate positive earnings, the concept of earnings growing faster or slower than revenue is not applicable, as the focus remains on the development of product candidates rather than scaling profitable operations. Klotho Neurosciences is not a dividend payer, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which explains that the company reinvests all available resources, including its cash reserves, directly into research and development activities rather than distributing income to shareholders. The overall growth and income profile is characterized by a reliance on future product milestones and clinical trial successes to drive value appreciation, rather than current cash flow generation or dividend income for investors.